Aromatase inhibitors

Endocrine-Related Cancer

Volumn 3, Issue 1, 1996, Pages 65-79

  Miller, W R ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; AROMATASE INHIBITOR; ENZYME INHIBITOR; EXEMESTANE; FADROZOLE; FORMESTANE; LETROZOLE; VOROZOLE;

BREAST CANCER; DRUG DEVELOPMENT; FEMALE; HUMAN; REVIEW;

EID: 0029968899     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.0.0030065     Document Type: Review

References (109)

1. Adams JB, Garcia M & Rochefort H 1981 Estrogenic effects of physiological concentrations of 5-androstene 3β17β diol and its metabolism in MCF-7 human breast cancer cells. Cancer Research 41 4720-4726.
2. Alonso-Munoz NC, Ojeda-Gonzalez MB, Beltran-Fabregat M, Dorcaa-Ribugent J, Lopez-Lopez L, Borras-Balada J, Cardenal-Alemany F, Gomez-Batiste Y, Fabregat-Mayol J & Viladiu-Quemada P 1988 Randomized trial of tamoxifen versus amino-glutethimide and versus combined tamoxifen and aminoglutethimide in advanced postmenopausal breast cancer. Oncology 45 350-353.
3. Baird DT, Uno A & Melby JC 1969 Adrenal secretion of androgens and oestrogens. Journal of Endocrinology 45 135-136.
4. Bajetta E, Zilembo N, Buzzoni R, Noberasco C, Celio L & Bichisao E 1993 Efficacy and tolerability of 4-hydroxyandrostenedione (4-OHA) as first-line treatment in postmenopausal patients with breast cancer after adjuvant therapy. Cancer Treatment Reviews 19 (Suppl B)31-36.
5. 1-testololactone. Journal of Clinical Endocrinology and Metabolism 49 672-676.
6. Bezwoda WR, Mansoor N & Dansey R 1987 Correlation of breast tumour aromatase activity and response to aromatase inhibition with aminoglutethimide. Oncology 44 345-349.
7. Bhatnagar AS & Hausler A 1987 Fortschritte in der Entwicklung neuer wirksamer und selektiver Aromatasehemmer. In Aromatasehemmer Neuer Perspektiven in der Behandlung des Mammakarzinoms, pp 23-28, Aktuelle Onkologie 38. Eds K Possinger & WR Miller, München: Verlag W Zuckschwerdt.
8. Bhatnager AS, Schieweck K, Häusler A, Browne LJ & Steele E 1989 Inhibitors of oestrogen biosynthesis: preclinical studies with CGS 16949A, a new nonsteroidal aromatase inhibitor. Proceedings of the Royal Society of Edinburgh 95B 293-303.
9. Bhatnagar AS, Hausler A, Schieweck K, Lang M & Bowman R 1990 Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor. Journal of Steroid Biochemistry and Molecular Biology 37 1021-1027.
10. Boccuzzi G, Brignardello E, Dimonaco D, Forte C, Leonardi L & Pizzini A 1992 Influence of dehydroepiandrosterone and 5-en-androstene-3-beta,17-beta-diol on the growth of MCF-7 human breast cancer cells induced by 17-beta estradiol. Anticancer Research 12 799-803.
11. Bonnefoi HR, Smith IE, Dowsett M, Trunet PF, Houston SJ, da Luz RJ, Rubens RD, Coombes RC & Powles TJ 1996 Therapeutic effects of the aromatase inhibitor fadrozole hydrochloride in advanced breast cancer. British Journal of Cancer 73 539-542.
12. Brodie AMH, Schwarzel WC, Sheikh AA & Brodie HJ 1977 The effect of an aromatase inhibitor, 4-hydroxyandrostenedione on estrogen-dependent processes in reproduction and breast cancer. Endocrinology 110 1684-1695.
13. Brodie AMH, Garnett WM, Hendrickson JR, Tsai-Morris CH, Marcotte PA & Robinson CH 1981 Inactivation of aromatase in vitro by 4-hydroxy-4-androstene-3,17-dione and 4-acetoxy-4-androstene-3,17-dione and sustained effects in vivo. Steroids 38 693-702.
14. Brodie AMH, Brodie HJ, Romanoff L, Williams JG, Williams KH & Wu JT 1982 Inhibition of estrogen biosynthesis and regression of mammary tumours by aromatase inhibitors. Hormones Cancer Advanced Experimental Medical Biology 138 179-190.
15. Bulun SE & Simpson ER 1994 Regulation of aromatase expression in human tissues. Breast Cancer Research and Treatment 30 19-29.
16. Bundred NJ, Eremin O, Stewart HJ, Dale BA & Forrest APM 1986 Beneficial response to pituitary ablation following aminoglutethimide. British Journal of Surgery 73 388-389.
17. Buzdar AU, Plourde PV, Jones SE, Voge CL, Wolters JM, Eisenberg PD & the North American Arimidex Study Group 1995 Randomized Phase II study of the new selective aromatase inhibitor Arimidex (A) (ZD1033) versus megestrol acetate (MA) in the treatment of postmenopausal women with advanced breast cancer. The Breast 4 256-257.
18. Chohan PB, Coombes RC, Foster AB, Harland SJ, Jarman M, Leung CS, Rowlands MG & Taylor GN 1982 Metabolism of aminoglutethimide in man; Desmolase and aromatase inhibition studies. Royal Society of Medicine International Congress and Symposium Series 53 19-21.
19. Cocconi G 1994 First generation aromatase inhibitors aminoglutethimide and testololactone. Breast Cancer Research and Treatment 30 57-80.
20. Coombes RC, Goss P, Dowsett M, Gazet J-C & Brodie A 1984 4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer. Lancer ii 1237-1239.
21. Coombes RC, Goss PE, Dowsett M, Hutchinson G, Cunningham D, Jarman M & Brodie AM.1987 4-Hydroxyandrostenedione treatment for postmenopausal patients with advanced breast cancer. Steroids 50 245-252.
22. Coombes RC, Stein RC & Dowsett M 1989 Aromatase inhibitors in human breast cancer. Proceedings of the Royal Society of Edinburgh 95B 283-291.
23. Cunningham D, Powles TJ, Dowsett M, Hutchinson G, Brodie AM, Ford HT, Gazet JC & Coombes RC 1987 Oral 4-hydroxyandrostenedione, a new endocrine treatment for disseminated breast cancer. Cancer Chemotherapy and Pharmacology 20 253-255.
24. Demers LM 1994 Effects of Fadrozole (CGS 16949A) and Letrozole (CGS 20267) on the inhibition of aromatase activity in breast cancer patients. Breast Cancer Research and Treatment 30 95-102.
25. Demers LM, Melby JC, Wilson TE, Lipton A, Harvey GA & Santen RJ 1990 The effects of CGS 16949A, an aromatase inhibitor on adrenal mineralocorticoid biosynthesis. Journal of Clinical Endocrinology and Metabolism 70 1162-1166.
26. Demers LM, Lipton A, Harvey HA, Hanagan J, Mulagha M & Santen RJ 1993a The effects of long term fadrozole hydrochloride treatment in patients with advanced stage breast cancer. Journal of Steroid Biochemistry and Molecular Biology 44 683-685.
27. Demers LM, Lipton A, Harvey HA, Kambic KB, Grossberg H, Brady C & Santen RJ 1993b The efficacy of CGS 20267 in suppressing estrogen biosynthesis in patients with advanced stage breast cancer. Journal of Steroid Biochemistry 44 687-691.
28. Dowsett M & Coombes RC 1994 Second generation aromatase inhibitor-4-hydroxy-androstenedione. Breast Cancer Research and Treatment 30 81-87.
29. Dowsett M, Harris AL, Smith IE & Jeffcoate SL 1984 Endocrine changes associated with relapse in advanced breast cancer patients on aminoglutethimide therapy. Journal of Clinical Endocrinology and Metabolism 58 99-104.
30. Dowsett M, Goss PE, Powles TJ, Hutchinson G, Brodie AM, Jeffcoate SL & Coombes RC 1987 Use of aromatase inhibitor 4-hydroxy-androstenedione in postmenopausal breast cancer: Optimization of therapeutic dose and route. Cancer Research 47 1957-1961.
31. Dowsett M, Cunningham DC, Stein RC, Evans S, Dehennin L, Hedley A & Coombes RC 1989 Doserelated endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients. Cancer Research 49 1306-1312.
32. Fishman J & Goto J 1981 Mechanisms of oestrogen biosynthesis: participation of multiple enzyme sites in placental aromatase hydroxylations. Journal of Biological Chemistry 256 4466-4471.
33. Geisler J, Lonning PE, Dowsett M, King N, Lundgren S, Ottestad L, Kormeset PO & Walton PL 1995 A randomised, double-blind multicentre crossover trial to evaluate in vivo inibition of aromatase by Arimidex (ZD1033) (1 mg and 10 mg PO OD) in postmenopausal women with breast cancer. The Breast 4 227.
34. Ginsburg E 1994 Environmental oestrogens. Lancet 343 284-285.
35. Goss PE & Gwyn KMEH 1994 Current perspectives on aromatase inhibitors in breast cancer. Journal of Clinical Oncology 12 2460-2470.
36. Goss PE, Clark RM, Ambus U, Weizel HAE, Wadden NA, Crump M, Walkde D, Tye LM, De Coster R & Bruynseels J 1995 Phase II study of Vorozole (R83842), a new aromatase inhibitor in postmenopausal women with advanced breast cancer in progression on tamoxifen. Clinical Cancer Research 1 287-294.
37. Graves PE & Salhanick HA 1979 Stereo selective inhibition of aromatase by enantiomers of aminoglutethimide. Endocrinology 105 52-57.
38. Griffiths CT, Hall TC, Saba Z, Barlow JJ & Nevinny HB 1973 Preliminary trial of aminoglutethimide in breast cancer. Cancer 32 31-37.
39. Grodin JM, Siiteri PK & MacDonald PC 1973 Sources of estrogen production in postmenopausal women. Journal of Clinical Endocrinology and Metabolism 36 207-214.
40. Hamon JT & Allegra JC 1988 Loss of hormonal responsiveness in cancer. In Endocrine Management of Cancer: Biological Basis, pp 61-71. Ed BA Stoll. Basel: Karger.
41. Harris AL 1985 Could aminoglutethimide replace adrenalectomy. Breast Cancer Research and Treatment 6 201-211.
42. Harris AL, Dowsett M, Jeffcoate SL, McKenna JA, Morgan M & Smith IE 1982a Endocrine and therapeutic effects of aminoglutethimide in premenopausal patients with breast cancer. Journal of Clinical Endocrinology and Metabolism 55 718-720.
43. Harris AL, Mitchell MD, Smith IE & Powles TJ 1982b Aminoglutethimide in the treatment of advanced postmenopausal breast cancer. Cancer Research Suppl 42 3405-3408.
44. 2 by aminoglutethimide in advanced breast cancer. British Journal of Cancer 48 595-598.
45. Harris AL, Dowsett M, Cantwell BMJ, Sainsbury JRC, Needham G, Farndon J & Wilson R 1986 Endocrine effects of low dose aminoglutethimide with hydrocortisone - an optimal hormone suppressive regime. Breast Cancer Research and Treatment Suppl 7 68-72.
46. Höffken K 1993 Experience with aromatase inhibitors in the treatment of advanced breast cancer. Cancer Treatment Reviews 19 (Suppl B) 37-44.
47. Höffken K, Jonat W, Possinger K, Kolbel M, Kunz T, Wagner H, Becher R, Callies R, Friederich P, Willmans W, Maas H & Schmidt CG 1990 Aromatase inhibition with 4-hydroxy-androstenedione in the treatment of postmenopausal patients with advanced breast cancer: a phase II study. Journal of Clinical Oncology 8 875-880.
48. Ingle JN, Green SJ, Ahmann DL, Long HJ, Edmondson JH, Rubin J, Chang MN & Creagan ET 1986 Randomized trial of tamoxifen alone or combined with aminoglutethimide and hydrocortisone in women with metastatic breast cancer. Journal of Clinical Oncology 4 958-964.
49. Isaacs JT 1988 Clinical heterogeneity in relation to response. In Endocrine Management of Cancer: Biological Basis, pp 125-145. Ed BA Stoll. Basel: Karger.
50. Iveson TJ, Smith IE, Ahern J, Smithers DA, Trunet PF & Dowsett M 1993 Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer. Cancer Research 53 266-270.
51. James VHT, Reed MJ, Adams EF, Ghilchick M, Lai LC, Coldham NG, Newton CJ, Purohit A, Owen AM, Singh A & Islam S 1989 Oestrogen uptake and metabolism in vivo. Proceedings of the Royal Society of Edinburgh 95B 185-193.
52. Johnston JO & Metcalf BW 1984 Aromatase: a target enzyme in breast cancer. In Novel Approaches to Cancer Chemotherapy, pp 307-328. London: Academic Press.
53. Johnston SRD, Smith IE, Doody D, Jacobs S, Robertshaw H & Dowsett M 1994 Clinical and endocrine effects of the oral aromatase inhibitor Vorozole in postmenopausal patients with advanced breast cancer. Cancer Research 54 5875-5881.
54. Jonat W, Howell A, Blomqvist CP, Eiermann W, Winblad G, Tyrrell CJ, Mauriac L, Roche H, Lundgren S, Hellmund R & Azab M 1995 A randomized trial of the new specific aromatase inhibitor 'Arimidex' (anastrozole) versus megesrol acetate (MA) in the treatment of postmenopausal women with advanced breast cancer (ABC). The Breast 4 227-228.
55. Judd HL, Judd GE, Lucas WE & Yen SS 1974 Endocrine function of the postmenopausal ovary: concentration of androgens and estrogens in ovarian and peripheral vein blood. Journal of Clinical Endocrinology and Metabolism 39 1020-1024.
56. Juranka PF, Zastawny RL & Ling V 1989 P-glycoprotein multidrug resistance and a super family of membraneassociated transport proteins. FASEB Journal 3 2583-2592.
57. Kadohama N, Yarborough C, Zhou D, Chen S & Osawa Y 1992 Kinetic properties of aromatase mutants Pro308Phe, Asp309Asn and Asp309Ala and their interactions with aromatase inhibitors. Journal of Steroid Biochemistry and Molecular Biology 43 693-701.
58. Lawrence DV, Lipton A, Harvey HA, Santen RJ, Wells SA, Cox CE & White DS 1980 Influence of estrogen receptor status on response of metastatic breast cancer to amindglutethimide. Cancer 45 786-791.
59. Lippman ME & Gellman EP 1995 Endocrine management of malignant disease. In Endocrinology, vol 3, ch 152, pp 2846-2869. Ed LJ DeGroot. Philadelphia: WB Saunder Co.
60. Lipton A & Santen RJ 1974 Medical adrenalectomy using aminoglutethimide and dexamethasone in advanced breast cancer. Cancer 33 503-512.
61. Lipton A, Harvey HA, Santen RJ, Boucher A, White D, Bernath A, Dixon R, Richards G & Shafik A 1982 A randomised trial of aminoglutethimide versus tamoxifen in metastatic breast cancer. Cancer 50 2265-2268.
62. Lipton A, Harvey HA, Demers LM, Hanagan JR, Mulagha MT, Kochak EM, Fitzsimmons S, Sanders SI &Santen RJ 1990 A phase I trial of CGS 16 949A. A new aromatase inhibitor. Cancer 65 1279-1285.
63. Lonning PE, Dowsett M, Jones A, Ekse D, Jacobs S, MacNeil F, Johannessen DC & Powles TJ 1992 Influence of aminoglutethimide on plasma oestrogen levels in breast cancer patients on 4-hydroxyandrostenedione treatment. Breast Cancer Research and Treatment 23 57-62.
64. MacDonald PC, Edman CD, Hemsell DL, Porter JC & Siiteri PK 1978 Effect of obesity on conversion of plasma androstenedione to estrone in postmenopausal women with and without endometrial cancer. American Journal of Obstetrics and Gynecology 130 448-455.
65. Masamura S, Adlercreutz H, Harvey H, Lipton A, Demers LM, Santen RJ & Santner SJ 1994 Aromatase inhibitor development for treatment of breast cancer. Breast Cancer Research and Treatment 33 19-26.
66. Means GD, Mahendroo M, Corbin CJ, Mathis JM, Powell FE, Mendelson CR & Simpson ER 1989 Structural analysis of the gene encoding human aromatase cytochrome P-450, the enzyme responsible for estrogen biosynthesis. Journal of Biological Chemistry 264 19385-19391.
67. Miller WR 1989 Aromatase inhibitors in the treatment of advanced breast cancer. Cancer Treatment Reviews 16 83-93.
68. Miller WR 1992 In vitro and in vivo effects of 4hydroxyandrostenedione on steroid and tumour metabolism. In 4-Hydroxyandrostenedione - A new Approach to Hormone-Dependent Cancer, pp 45-50. Eds RC Coombes & M Dowsett. London: Royal Society of Medicine Services Ltd International Congress and Symposium Series.
69. Miller WR & Forrest APM 1974 Oestradiol synthesis from C19 steroids by human breast cancer. British Journal of Cancer 33 16-18.
70. Miller WR & O'Neill JS 1988 The importance of local synthesis of estrogen within the breast. Steroids 50 537-548.
71. Miller WR & O'Neill JS 1989 The relevance of local estrogen metabolism within the breast. Proceedings of the Royal Society of Edinburgh 95B 203-217.
72. Miller WR, Hawkins RA, Mullen P, Sourdaine P & Telford J 1995 Aromatase inhibition: determinants of response and resistance. Endocrine-Related Cancer 2 73-85.
73. Milsted R, Habesgaw T, Kayes S, Sangster G, Macbeth F, Campbell-Ferguson J, Smith D & Calman K 1985 A randomized trial of tamoxifen versus tamoxifen with aminoglutethimide in postmenopausal women with advanced breast cancer. Cancer Chemotherapy and Pharmacology 14 272-273.
74. Murray FT, Santner S, Samojlik EA & Santen RJ 1979 Serum aminoglutethimide levels: studies of serum halflife, clearance and patient compliance. Journal of Clinical Pharmacology 19 704-711.
75. Murray R & Pitt P 1985 Low-dose aminoglutethimide without steroid replacement in the treatment of postmenopausal women with advanced breast cancer. European Journal of Cancer and Clinical Oncology 21 19-22.
76. Newsome HH, Brown PN, Terz JJ & Lawrence W 1977 Medical and surgical adrenalectomy in patients with advanced breast carcinoma. Cancer 39 542-546.
77. Nissen-Meyer R 1965 Castration as part of the primary treatment for operable female breast cancer. Acta Radiologica Suppl 249 1-133.
78. Perel E & Killinger DW 1979 The interconversion and aromatization of androgens by human adipose tissue. Journal of Steroid Biochemistry 10 623-627.
79. Perez-Carrion R, Alberola CV, Calabresi F, Michel RT, Santos R, Delozier T, Goss P, Mauriac L, Feuilhade F, Freue M, Pannuti F, Van Belle S, Martinez J, Wehrle E & Royce CM 1994 comparison of the selective aromatase inhibitor formestane with tamoxifen as firstline hormonal therapy in postmenopausal women with advanced breast cancer. Annals of Oncology 5 S19-S24.
80. Petru E & Schmahl D 1987 On the role of additive monotherapy with tamoxifen, medroxyprogesterone acetate and aminoglutethimide on advanced breast cancer. Klinische Wochenshrift 65 959-966.
81. Pickles T, Perry L, Murray P & Plowman P 1990 4-Hydroxyandrostenedione - Further clinical and extended endocrine observations. British Journal of Cancer 62 309-313.
82. Plourde PV, Dyroff M & Dukes M 1994 Arimidex (TM): A potent and selective fourth-generation aromatase inhibitor. Breast Cancer Research and Treatment 30 103-111.
83. Santen RJ 1982 Overall experience with aminoglutethimide in the management of advanced breast carcinoma. In Aminoglutethimide: An Alternative Endocrine Therapy for Breast Carcinoma, p 3-7. Eds RW Elsdon-Dew, IM Jackson & GFB Birdwood. London: Academic Press.
84. Santen RJ & Misbin RI 1981 Aminoglutethimide: review of pharmacology and clinical use. Pharmacotherapy 1 95-120.
85. Santen RJ, Santner S, Davis B, Veldhuis J, Samojlik E & Ruby E 1978 Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast cancer. Journal of Clinical Endocrinology and Metabolism 47 1257-1265.
86. Santen RJ, Samojlik E & Worgul TJ 1981a Aminoglutethimide produce profile. In Pharmanual: A Comprehensive Guide to the Therapeutic Use of Aminoglutethimide, pp 101-160. Eds RJ Santen & IC Henderson. Basel: S Karger.
87. Santen RJ, Worgul TJ, Samojlik E, Interroule A, Boucher AE, Lipton A, Harvey HA, White DS, Smart E, Cox C & Wells SA 1981b A randomised trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer. New England Journal of Medicine 305 545-551.
88. Santen RJ, Manni A, Harvey H & Redmond C 1990 Endocrine treatment of breast cancer in women. Endocrine Reviews 11 1-45.
89. Santen RJ, Demers LM, Lynch J, Harvey H, Lipton A, Mulagha M, Hanagan J, Garber JE, Henderson IC, Navari RM & Miller AA 1991 Specificity of low dose fadrazole hydrochloride (CGS 16949A) as an aromatase inhibitor. Journal of Clinical Endocrinology and Metabolism 73 99-106.
90. Schieweck K, Bhatnagar AS & Matter A 1988 CGS16949A, a new nonsteroidal aromatase inhibitor, effects on hormone-dependent and independent tumors in vitro. Cancer Research 48 834-839.
91. Schweikert HU, Milewich L & Wilson JD 1976 Aromatization of androstenedione by cultured human fibroblasts. Journal of Clinical Endocrinology and Metabolism 43 785-795.
92. 1-Testololactone: clinical trials. Cancer Research Suppl 42 3387-3388.
93. Setchell KDP, Borriello SP, Hulme P, Kirk DN & Axelson M 1984 Nonsteroidal estrogens of dietary origin: possible roles in hormone-dependent disease. American Journal of Clinical Nutrition 40 569-578.
94. Sharpe RM 1994 Could environmental oestrogenic chemicals be responsible for some disorders of human male reproductive development? Current Opinion in Urology 4 295-301.
95. Smith IE, Harris AL, Morgan M, Ford HT, Gazet JC, Harmer CL, White H, Parsons CA, Villards A, Walsh G & McKenna JA 1981 Tamoxifen versus aminoglutethimide in the treatment of advanced breast carcinoma. A control randomised cross-over trial. British Medical Journal 283 1432-1434.
96. Smith IE, Harris AL, Morgan M, Gazet J-C & McKenna JA 1982 Tamoxifen versus aminoglutethimide versus combined tamoxifen and aminoglutethimide in the treatment of advanced breast carcinoma. Cancer Research 42 3430-3433.
97. Smith IE, Stuart-Harris R, Harris AL & Dowsett M 1984 Aminoglutethimide alone and in combination in the treatment of advanced breast cancer: clinical and endocrine aspects. In Breast Cancer: Therapeutic Modalities Current and Future, pp 145-149. Eds HA Harvey, A Lipton & MA Michaels. Mississauga, Canada: MES Medical Education Services.
98. Smith IE, Iveson TJ, Trunet P & Dowsett M 1994 CGS20267, a new oral non-steroidal aromatase inhibitor in the treatment of postmenopausal patients with advanced breast cancer, a phase I clinical study. Advances in Clinical Oncology 2 179-185.
99. Sourdaine P, Parker MG, Telford J & Miller WR 1994 Analysis of the aromatase cytochrome P450 gene in human breast cancers. Journal of Molecular Endocrinology 13 331-337.
100. Stein RC, Dowsett M, Davenport J, Hedley A, Ford HT, Gazet JC & Coombes RC 1990a Preliminary study of the treatment of advanced breast cancer in postmenopausal women with the aromatase inhibitor CGS 16949A. Cancer Research 50 1381-1384.
101. Stein RC, Dowsett M, Hedley A, Gazet JC, Ford HT & Coombes RC 1990b The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer. British Journal of Cancer 62 679-683.
102. Stein RC, Dowsett M & Coombes RC 1994 Studies of formestane alone and in combination with goserelin in premenopausal breast cancer. Advances in Clinical Oncology 2 149-154.
103. Strocchi E, Camaggi CM, Martoni A, Cellerino R, Miseria S, Malacarne P, Indelli M, Balli M, Bonciarelli G, Ambroso G, Bichisao E, Robustelli Della Cuna G & Pannuti F 1991 Aminoglutethimide in advanced breast cancer: plasma levels and clinical results after low and high doses. Cancer Chemotherapy Pharmacology 27 451-455.
104. Taylor RE, Powles TJ, Humphreys J, Bettelheim R, Dowsett M, Casey AJ, Neville AM & Coombes R 1982 Effects of endocrine therapy on steroid receptor content of breast cancer. British Journal of Cancer 45 80-85.
105. Vanden Bossche H, Moereels H & Koymans LMH 1994 Aromatase inhibitors - mechanisms for non-steroidal inhibitors. Breast Cancer Research and Treatment 30 43-55.
106. Vermeulen A & Verdonck L 1978 Sex hormone concentrations in postmenopausal women. Clinical Endocrinology 9 59-66.
107. van der Wall E, Donker TH, de Frankrijker E, Mortier HWR, Thijssen JHH & Blankenstein RA 1993 Inhibition of the in vivo conversion of androstenedione to estrone by the aromatase inhibitor vorozole in healthy postmenopausal women. Cancer Research 53 4563-4566.
108. Wouters W, Snoeck E & De Coster R 1994 Vorozole, a specific non-steroidal aromatase inhibitor. Breast Cancer Research and Treatment 30 89-94.
109. Yates RA, Dowsett M, Fisher GV, Selen SA & Wyld PJ 1996 Arimidex (ZD1033): A selective, potent inhibitor of aromatase in postmenopausal female volunteers. British Journal of Cancer (In Press).